Repurposing Natural Compounds to Target SARS-CoV-2 Protease and Spike RBD: Molecular Docking Insights

Study Background and Research Question

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has resulted in a global health crisis, necessitating the rapid identification of effective treatments. The virus relies on two critical proteins for successful infection and replication: the main protease (3CL^pro, also known as M^pro) and the receptor-binding domain (RBD) of the spike (S) protein. The 3CL^pro enzyme is indispensable for proteolytic cleavage of viral polyproteins, which is essential for viral replication, while the spike RBD mediates entry into host cells via interaction with the human ACE2 receptor. Targeting these proteins with inhibitors could potentially disrupt the infection cycle at multiple stages. The central research question of the reference study is whether natural, safe, and accessible compounds can bind to these viral targets effectively, offering candidates for drug repurposing in response to COVID-19.

Key Innovation from the Reference Study

The innovative aspect of this work lies in its comprehensive in silico screening of natural compounds, specifically vitamins, against both the SARS-CoV-2 3CL^pro and spike RBD. Unlike previous studies that focused on synthetic inhibitors or a single viral target, this research systematically evaluates the dual potential of vitamins to inhibit viral entry and replication. The study identifies bentiamine, folic acid, benfotiamine, and vitamin B12 as strong binders to the S protein RBD, and bentiamine, folic acid, fursultiamine, and riboflavin as candidates for 3CL^pro inhibition. This approach leverages the safety profile and accessibility of these compounds, widening the scope of antiviral therapeutics research and highlighting new avenues for rapid deployment in pandemic settings.

Methods and Experimental Design Insights

The authors employed a multi-step computational pipeline to identify promising repurposing candidates. The process began with virtual screening of vitamins sourced from a commercial compound library, using molecular docking to predict their binding affinities to the SARS-CoV-2 3CL^pro and spike RBD. The structural models for docking were based on high-resolution crystallographic data of the viral proteins. Key residues within the S protein RBD (notably R403, K417, Y449, Y453, N501, Y505) and the 3CL^pro active site (His41 and Cys145) were emphasized as critical interaction points. Promising ligand-protein complexes were further evaluated by molecular dynamics simulations to assess the stability and strength of binding over time, providing a dynamic perspective beyond static docking scores.

Protocol Parameters

• Docking preparation: Compounds optimized using energy minimization; protein structures prepared with all water molecules removed and hydrogens added.
• Docking grid: Centered on key catalytic residues (His41, Cys145 for 3CL^pro; R403, K417, Y449, etc., for S-RBD), ensuring accurate ligand placement.
• Molecular dynamics: Simulations performed on top-ranked docked complexes (e.g., ligand-3CL^pro and ligand-S-RBD) for up to 100 ns to evaluate binding stability.
• Binding energy analysis: MM/PBSA calculations used to estimate the free energy of binding across simulation trajectories.

Core Findings and Why They Matter

The study found that several vitamins, notably bentiamine, folic acid, benfotiamine, vitamin B12, fursultiamine, and riboflavin, exhibit strong and stable binding to either the spike RBD or 3CL^pro. For the S protein RBD, these compounds interact with residues critical for ACE2 binding, suggesting potential to block viral entry. For 3CL^pro, interactions with the catalytic dyad (His41 and Cys145) and surrounding substrate-binding residues indicate a plausible mechanism for inhibiting viral polyprotein processing. Molecular dynamics simulations confirmed that these ligand-protein complexes remained stable over time, supporting the hypothesis that these compounds could disrupt key steps in the SARS-CoV-2 life cycle. The dual targeting of entry and replication mechanisms is especially significant for developing combination therapies or broad-spectrum antiviral strategies. Importantly, the safety and availability of these vitamins could facilitate rapid translation to clinical studies, pending in vitro and in vivo validation.

Comparison with Existing Internal Articles

While the reference paper focuses on the repurposing of natural compounds using computational methods, a number of internal articles provide complementary perspectives on direct-acting antivirals, especially synthetic inhibitors such as Nirmatrelvir (PF-07321332). For instance, internal resources on Nirmatrelvir detail applied workflows for SARS-CoV-2 3CL protease inhibition, offering experimental guidance for both in vitro and translational research. These articles highlight the reproducibility, purity, and well-characterized mechanism of Nirmatrelvir, which directly targets the same 3CL^pro protease assessed in the reference study. The internal workflows also address practical laboratory challenges, such as assay optimization and data integrity, bridging the gap between in silico predictions (as in the reference paper) and real-world experimental implementation. This synergy underscores the translational potential of computational findings, especially when paired with validated reagents.

Limitations and Transferability

Despite the promising in silico results, the reference study’s findings remain predictive until validated by experimental and clinical data. Docking and molecular dynamics simulations provide valuable insights into potential binding modes and stability, but they cannot fully capture the complexity of cellular context, drug metabolism, or potential off-target effects. The actual efficacy of these vitamins as antiviral agents will depend on factors such as bioavailability, cellular uptake, and achievable concentrations in vivo. Furthermore, while the study highlights the utility of safe, widely available compounds, translation to clinical use requires rigorous pharmacological and toxicological assessment. Nonetheless, the computational pipeline established can be readily adapted for screening other compound libraries or viral targets, enhancing its transferability to future antiviral research.

Why this cross-domain matters, maturity, and limitations

This research bridges computational drug discovery and experimental antiviral therapeutics, demonstrating how in silico screening can rapidly identify new candidates for laboratory validation. However, the maturity of this approach depends on subsequent experimental confirmation, as virtual binding does not always predict biological activity. The integration of computational and experimental workflows, as exemplified by internal articles on Nirmatrelvir, offers a pathway toward robust, reproducible, and scalable antiviral research.

Research Support Resources

For researchers seeking to experimentally validate SARS-CoV-2 3CL protease inhibition, high-purity small molecule inhibitors are essential. Nirmatrelvir (PF-07321332) (SKU B8579) is an orally bioavailable, selective inhibitor of the SARS-CoV-2 3CL^pro protease, widely used in antiviral research due to its defined mechanism and robust quality control. While the reference study focuses on natural compound screening, Nirmatrelvir provides a benchmark for assay development and comparative studies. Researchers can leverage this compound, available from APExBIO, to design, optimize, and interpret cell-based or biochemical assays targeting coronavirus replication.